摘要 |
Use of benzo(c)quinolizinium derivatives (I) in medicines for the treatment of pathological states due to constriction of smooth muscle cells, is new. Use of benzo(c)quinolizinium derivatives of formula (I) in medicines for the treatment of pathological states due to constriction of smooth muscle cells, is new. A = an aromatic or non-aromatic heterocycle, and if non-aromatic the nitrogen atom is attached to the 4a carbon atom by a double bond; R1-R5, R7-R10 = H, halo, 1-10 C alkyl, alkoxy, carbonyl, oxycarbonyl or ester (all optionally substituted by T), 5-10C aliphatic or aromatic ring (optionally substituted by T1), -OR1 or -NRbRc; or R1+R2, R2+R3, R3+R4, R4+R5, R7+R8, R8+R9, or R9+R10 = 5-10C aromatic or aliphatic ring optionally substituted by T1; or R3+R4 = indolyl substituted by Ra; T = halo, OH, primary, secondary or tertiary amino, or 5-10C aromatic or aliphatic rings that may themselves be optionally substituted; T1 = halo, OH, primary, secondary or tertiary amino; Ra-Rc = H, alkyl, carbonyl, oxycarbonyl, ester, or an aromatic or aliphatic ring; Y = -ORd, -NReRf; Rd-Rf = H, alkyl, alkoxy, carbonyl, oxycarbonyl, ester, or an aromatic or aliphatic ring; or Rd+R5, Rd+R7, Re+R5, Re+R7, Rf+R5, Rf+R7 = 5-10C aromatic or aliphatic ring optionally substituted by T1; X- = anion, e.g. halo or perchlorate. Independent claims are also included for new compounds (I; R5 = -COOR'). R' = 1-10C alkyl, especially ethyl.
|